Skip to Content
Stock Strategist

Growing Healthcare IT Demand Benefits Cerner

Although revenue issues continue, we think the shares are undervalued.


Although  Cerner's (CERN) fourth-quarter results met our expectations, we've lowered our fair value estimate to $63 per share from $69. The management team once again missed its own revenue guidance, and we believe the firm is experiencing increasing pressure in its operating environment. Considering these latest developments, we now believe top-line growth will moderate slightly faster than we initially expected. Additionally, we believe competition from current and new healthcare information technology players has accelerated, given the growing need of providers to build in new reimbursement infrastructure and the prime opportunity this presents to the entire healthcare IT market. As a result, we believe Cerner will see greater sales and research and development expenses over the medium term than we initially expected. These modeling adjustments lead to a reduction in our explicit forecast revenue growth and operating margin expansion assumptions. Nevertheless, the stock trades below our reduced fair value estimate, presenting investors with an opportunity to acquire shares of a solid healthcare firm at a material discount.

We are highly disappointed that management has missed its own revenue guidance over the past several quarters. We believe management's missteps have built in an increased level of uncertainty for the firm. We will watch closely how this trend develops over the coming quarters and expect the missed guidance pattern to reverse over the course of 2016. We believe this issue points to a shift among Cerner's customer base as hospitals and medical service providers are now demanding greater value from their healthcare IT vendors. Additionally, we believe new entrants like UnitedHealth and traditional rivals such as Epic Systems have increased their sales efforts and are now willing to accept less advantageous payment terms. The confluence of these factors has caused Cerner to experience a delay in revenue growth and margin expansion.

Vishnu Lekraj does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.